TEVOGEN BIO
A clinical stage biotech company developing curative and preventative treatments to positively impact global public health. Tevogen is developing T cell immunotherapies in virology, oncology, and neurology, by utilizing patented precision T cell platform technology. Its current intellectual property portfolio includes several breakthrough cell and gene therapy platforms.
TEVOGEN BIO
Industry:
Biopharma Biotechnology Health Care Life Science Medical Oncology Pharmaceutical Product Research Therapeutics
Founded:
2020-01-01
Address:
Warren, New Jersey, United States
Country:
United States
Website Url:
http://www.tevogen.com
Total Employee:
11+
Status:
Active
Contact:
1 877 838-6436
Email Addresses:
[email protected]
Total Funding:
58 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Font Awesome Global Site Tag Organization Schema
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
CSTS Health Care
Biotech, Precision Oncology, Platelet Facilitated Drugs (PFDs)
IACT Health
IACT Health is a research and development firm that performs clinical trials for oncology, cardiology, pulmonology and endocrinology.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Omnia Biosystems
Omnia Biosystems is addressing challenging targets in oncology using artificial intelligence.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
HMP Partners
HMP Partners investment in Series B - Tevogen Bio
HMP Partners
HMP Partners investment in Venture Round - Tevogen Bio
Key Employee Changes
Official Site Inspections
http://www.tevogen.com Semrush global rank: 10.77 M Semrush visits lastest month: 202
- Host name: 192.0.78.163
- IP address: 192.0.78.163
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
More informations about "Tevogen Bio"
Home - Tevogen.ai
Jan 23, 2025 Since entering our agreement with Microsoft, Tevogen.AI has been creating the base for its PredicTcell platform to develop multiple foundational models. This entailed expanded our dataset of viruses and diseases backed …See details»
Tevogen Bio - Crunchbase Company Profile & Funding
A clinical stage biotech company developing curative and preventative treatments to positively impact global public health. Tevogen is developing T cell …See details»
Tevogen Bio Inc. - Investor Relations
Apr 28, 2025 At Tevogen Bio Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are …See details»
Tevogen Bio - VentureRadar
" Tevogen’s unique T cell therapy approach is a major scientific breakthrough under development and investigation to treat COVID-19, Influenza, almost all Solid Tumors and common …See details»
Tevogen Bios Long-Term Vision Amidst Financial Struggles
Apr 15, 2025 In a climate where biotechnology firms are under increasing pressure to demonstrate financial viability, Dr. Ryan Saadi, the CEO and founder of Tevogen Bio Holdings …See details»
About - Tevogen
Sadiq Khan, MBA, joins Tevogen to lead its Global Commercial organization. He brings over 30 years of commercial leadership, operations, and alliance management experience. Most …See details»
Tevogen CEO Reaffirms the Company’s Commitment to Closing …
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing …See details»
Tevogen Bio Prepares Organizational Readiness to Support …
Nov 26, 2024 “Tevogen’s C.O.R.E. values reflect leaderships commitment to embracing diverse perspectives, encouraging a readiness to learn, and creating solutions with a shared purpose,” …See details»
Tevogen charts new path of expansion and medical innovation at …
Apr 25, 2025 From Tevogen’s perspective, CIC offered not only the space, but also the state-of-the-art shared equipment and support structure they needed, exactly when they needed it. For …See details»
Tevogen Bio Holdings Inc. Secures $50 Million Agreement with
Apr 28, 2025 Potential Positives. Tevogen has secured an agreement with CD8 Technology Services LLC that provides up to $50 million, enhancing its dedicated R&D and manufacturing …See details»
Tevogen Bio Inc. - Tevogen Bio Prepares Organizational Readiness …
WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) - Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing …See details»
Tevogen Bio Prepares Organizational Readiness to Support
Nov 26, 2024 Tapan V Shah, Head of Investor Relations and Corporate Development, will take on added responsibility for US Government Affairs and Policy. William Keane, Vice President …See details»
Technology - Tevogen
Tevogen’s commercial scale ready manufacturing process yields a highly efficient ratio of doses per cell donor. ExacTcell focuses on the selection and expansion of naturally occurring, …See details»
Tevogen Bio Inc. - Tevogen Bio CEO Reflects on Public Support ...
WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) - Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing …See details»
Newsroom - Tevogen
6 days ago Tevogen Bio – May 2, 2025. CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment. …See details»
Investors - Tevogen
Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen’s …See details»
Tevogen Bio Prepares Organizational Readiness to Support …
Nov 26, 2024 Warren, N.J., Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically …See details»
Pipeline - Tevogen
Tevogen Bio is developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy. Addition of non-oncology products to the …See details»
Tevogen Bio Inc. - Tevogen CEO Expresses Gratitude for …
WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) - Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) is a clinical-stage specialty immunotherapy biotech …See details»
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 …
Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts. Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701See details»